Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Expands By 264.5%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 572,600 shares, an increase of 264.5% from the January 15th total of 157,100 shares. Based on an average daily trading volume, of 1,130,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 55.1% of the company’s stock are sold short.

CERo Therapeutics Stock Down 0.3 %

CERO stock traded down $0.01 on Thursday, hitting $1.80. 15,375 shares of the company’s stock were exchanged, compared to its average volume of 983,302. The firm has a 50 day moving average price of $4.59 and a two-hundred day moving average price of $10.00. CERo Therapeutics has a 12-month low of $1.70 and a 12-month high of $1,238.00.

Insider Buying and Selling

In related news, major shareholder Bioventures Opportunities G. Yk sold 29,989 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.00, for a total transaction of $179,934.00. Following the transaction, the insider now directly owns 130,051 shares in the company, valued at $780,306. The trade was a 18.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 64,300 shares of company stock worth $529,409 in the last ninety days. 18.00% of the stock is owned by insiders.

Institutional Trading of CERo Therapeutics

A hedge fund recently raised its stake in CERo Therapeutics stock. Avantax Planning Partners Inc. raised its position in shares of CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) by 89.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,585,151 shares of the company’s stock after purchasing an additional 1,224,021 shares during the quarter. Avantax Planning Partners Inc. owned 172.00% of CERo Therapeutics worth $155,000 at the end of the most recent reporting period. Institutional investors own 29.64% of the company’s stock.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.